Perrigo rolls out AB rated generic version of Epiduo Gel

Perrigo Company sought U.S FDA’s approval for the launch of generic version of Epiduo (adapalene and benzoyl peroxide) Gel, 0.1%/2.5%.

Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, “This launch exemplifies Perrigo’s commitment to developing and launching products within the extended topicals category. Our robust R&D pipeline remains focused on introducing more products that will create savings for patients and the U.S. healthcare system.”

According to IMS Health, Epiduo Gel is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Market sales of Epiduo Gel over the last 12 months were approximately $164 million.